佐力药业拟3.56亿元收购未来医药多种微量元素注射液资产组

Core Viewpoint - Zhaoli Pharmaceutical (300181.SZ) announced the acquisition of a multi-trace element injection asset group from Tibet Future Biopharmaceutical Co., Ltd. for a total price of RMB 356 million, which includes both marketed and research products, enhancing the company's product structure and expanding its treatment areas [1][2]. Group 1 - The acquisition includes the marketed products "Multi-trace Element Injection (I)" and "Multi-trace Element Injection (II)", as well as the research product "Multi-trace Element Injection (III)" [1]. - The asset group is expected to optimize the company's product structure and broaden its focus on disease treatment and health management for women, children, and the elderly, aligning with the national health development strategy [1]. - The asset group generated a net profit of RMB 45.79 million from January to September 2025, indicating strong profitability [2].